CRISPR Therapeutics AG (NASDAQ:CRSP - Get Free Report) Director John Greene purchased 7,000 shares of the firm's stock in a transaction on Wednesday, February 26th. The shares were purchased at an average price of $44.85 per share, with a total value of $313,950.00. Following the completion of the acquisition, the director now directly owns 7,000 shares of the company's stock, valued at approximately $313,950. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link.
CRISPR Therapeutics Stock Performance
CRISPR Therapeutics stock traded up $1.16 during trading hours on Tuesday, hitting $43.45. 2,083,127 shares of the stock were exchanged, compared to its average volume of 2,326,432. The stock has a market capitalization of $3.73 billion, a P/E ratio of -9.94 and a beta of 1.67. The business's 50-day moving average is $42.52 and its two-hundred day moving average is $45.89. CRISPR Therapeutics AG has a 12 month low of $36.52 and a 12 month high of $83.50.
CRISPR Therapeutics (NASDAQ:CRSP - Get Free Report) last released its quarterly earnings results on Tuesday, February 11th. The company reported ($0.44) EPS for the quarter, topping analysts' consensus estimates of ($1.15) by $0.71. CRISPR Therapeutics had a negative return on equity of 18.46% and a negative net margin of 981.54%. On average, equities analysts predict that CRISPR Therapeutics AG will post -5.16 earnings per share for the current fiscal year.
Analysts Set New Price Targets
Several analysts recently weighed in on CRSP shares. Citigroup decreased their target price on CRISPR Therapeutics from $89.00 to $82.00 and set a "buy" rating for the company in a research note on Tuesday, February 18th. TD Cowen raised CRISPR Therapeutics from a "sell" rating to a "hold" rating and set a $35.00 price objective for the company in a research report on Wednesday, February 12th. Chardan Capital dropped their target price on shares of CRISPR Therapeutics from $94.00 to $84.00 and set a "buy" rating on the stock in a research report on Thursday, February 13th. Cantor Fitzgerald reissued a "neutral" rating on shares of CRISPR Therapeutics in a report on Wednesday, February 19th. Finally, Barclays raised their price target on shares of CRISPR Therapeutics from $55.00 to $56.00 and gave the stock an "equal weight" rating in a research report on Wednesday, February 12th. Two investment analysts have rated the stock with a sell rating, nine have assigned a hold rating and twelve have issued a buy rating to the company. According to data from MarketBeat, the company has a consensus rating of "Hold" and a consensus target price of $74.40.
Read Our Latest Analysis on CRISPR Therapeutics
Hedge Funds Weigh In On CRISPR Therapeutics
A number of institutional investors have recently modified their holdings of CRSP. ARK Investment Management LLC increased its holdings in shares of CRISPR Therapeutics by 19.7% in the fourth quarter. ARK Investment Management LLC now owns 8,973,064 shares of the company's stock valued at $353,180,000 after purchasing an additional 1,474,439 shares in the last quarter. Capital International Investors increased its stake in shares of CRISPR Therapeutics by 10.3% in the 4th quarter. Capital International Investors now owns 8,743,523 shares of the company's stock valued at $344,145,000 after buying an additional 816,789 shares during the period. T. Rowe Price Investment Management Inc. raised its position in shares of CRISPR Therapeutics by 39.2% during the fourth quarter. T. Rowe Price Investment Management Inc. now owns 3,811,708 shares of the company's stock worth $150,029,000 after acquiring an additional 1,074,238 shares during the last quarter. State Street Corp raised its position in shares of CRISPR Therapeutics by 25.0% during the third quarter. State Street Corp now owns 2,992,988 shares of the company's stock worth $140,611,000 after acquiring an additional 599,304 shares during the last quarter. Finally, FMR LLC lifted its stake in shares of CRISPR Therapeutics by 1.0% during the third quarter. FMR LLC now owns 2,376,166 shares of the company's stock valued at $111,632,000 after acquiring an additional 23,075 shares during the period. 69.20% of the stock is owned by institutional investors.
About CRISPR Therapeutics
(
Get Free Report)
CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases.
Further Reading
Before you consider CRISPR Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CRISPR Therapeutics wasn't on the list.
While CRISPR Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
